QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Surgery Partners, Inc. (SGRY)

Healthcare

Actionable
Fundamental
3
Sentiment
3
Technical
4

Bullish pullback entry: buy limit 14.30 at the 10-13 retest shelf (low 14.255/14.26) within the higher-lows recovery, MACD zero-cross and price above sma20/sma50/sma200; protective stop 13.64 (1.0xATR pullback floor under structural 13.96; below the 10-14 low 14.085 and sma20); targets 15.62/16.61; R/R 2.00; no earnings/dividend events inside the 15-day window.

Analysis as of 2026-10-15· more than 2 trading days ago

Company overview

Surgery Partners, Inc. operates a network of surgical facilities across the United States, offering non-urgent surgical procedures in specialties such as gastroenterology, ophthalmology, and orthopedics. The company runs ambulatory surgery centers and surgical hospitals, providing ancillary services like diagnostic imaging and anesthesia. As of December 31, 2021, it managed 126 facilities across 31 states.

Fundamental

fair
Fundamental3
Mixed fundamentals

Surgery Partners shows mixed fundamentals with steady cash flow but elevated leverage and GAAP losses.

Surgery Partners posts steady top-line growth and reliable operating/free cash flow, and just completed a $587M-net-proceeds hospital sale that trims net debt to ~$2.7B pro forma and sharpens its pure-play surgical focus. But GAAP losses persist, leverage stays elevated (~6.8x net debt/EBITDA, ~1.4x interest coverage), and Q2 margins softened — mixed, improving fundamentals with real balance-sheet risk; a watchlist candidate pending further deleveraging.

Sentiment

fair
Sentiment3
Forming sentiment

Sentiment is mildly positive, with a constructive outlook but no immediate catalysts.

Dominant catalyst is the completed Idaho Falls divestiture (announced; closed 2026-09-17; $797M gross / $587M net proceeds to debt; leverage ~4.4x to ~4.1x), which the tape rewarded with a ~+15.7% late-September re-rating but which now trails 28 days and no longer qualifies as an actionable short-term catalyst. Media sentiment is flat (scoring ≈ +0.17 vs baseline ≈ +0.15, both mildly positive), retail is indeterminate, and the Red-Flag Screen is clean; with the next driver (Q3 results) still undated, the setup is a mixed/forming one rather than actionable-now.

Technical

good
Technical4
Higher-lows recovery

The stock is in a higher-lows recovery trend, supported by a MACD zero-cross and price above key averages.

SGRY is in a higher-lows recovery: closes rose from 13.23 (10-01) to 14.55 (10-13), 10-14 closed 14.83 above the sma200, and price 14.77 now sits above sma20 14.09 / sma50 14.23 / sma200 14.45 with EMA9 14.27 above EMA21 14.13 (fresh cross on 10-14). Momentum confirms: MACD line crossed above zero on 10-15 (0.05 vs signal -0.09, histogram +0.14 and expanding), RSI14 57.3 constructive, ADX14 15.7 rising from 11.3. The single weak signal is 10-15's intraday rejection at 15.34 (close 14.77, -0.40%, under the day's VWAP 14.945), which argues for buying the pullback rather than chasing. Plan: limit 14.30 at the 10-13 retest shelf; stop 13.64 = entry - 1.0xATR (Change-A pullback floor under structural 13.96, which sits below the 10-14 low 14.085 and sma20 14.09); targets 15.62 / 16.61; R/R 2.00.

You’re looking at 2026-10-15 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.